Examkin

Question

Difficulty: HardPreventive Care and Screening

A 31-year-old G2P1 woman at 28 weeks gestation presents to the clinic for a routine prenatal visit. Her pregnancy has been uncomplicated to date. Her medical history is significant for mild intermittent asthma, which is well-controlled with an albuterol inhaler as needed. She feels well and reports normal fetal movement. Her blood type is AB-positive. Review of her immunization records shows that she received a complete series of standard childhood vaccines. She also received a tetanus-diphtheria-acellular pertussis (Tdap) vaccine two years ago during the third trimester of her first pregnancy. An inactivated influenza vaccine was administered three weeks ago. Vital signs and physical examination are unremarkable. Fundal height is 28 cm, and the fetal heart rate is 145/min. Which of the following is the most appropriate preventive intervention for this patient at today's visit?

  1. Administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccineAnswer
  2. B
    Administration of anti-D immune globulin
  3. C
    Screening for group B Streptococcus colonization
  4. D
    Administration of the 20-valent pneumococcal conjugate vaccine (PCV20)
  5. E
    Administration of the measles-mumps-rubella (MMR) vaccine

Answer

Administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine
The administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine is the most appropriate intervention. The Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) strongly recommend that all pregnant women receive a Tdap vaccine during every pregnancy, optimally between 27 and 36 weeks of gestation. This recommendation applies regardless of the interval since the patient's last Tdap vaccination. The rationale is to maximize the maternal antibody response, which facilitates the passive transplacental transfer of IgG antibodies to the fetus. This provides the newborn with critical protection against pertussis (whooping cough) during the vulnerable first few months of life before they are old enough to receive their own primary DTaP series.

Step-by-Step Solution

1
Analyze the patient's gestational age and current risk profile.
The patient is at 28 weeks gestation, has a positive Rh blood type, and has a history of a Tdap vaccine 2 years ago.
Gestational age and prior medical history dictate the specific timing of routine prenatal preventive interventions.
2
Evaluate the indication for the Tdap vaccine.
Tdap is required.
Current guidelines mandate a Tdap booster during every single pregnancy (ideally between 27 and 36 weeks) to provide the fetus with passive immunity against pertussis, regardless of how recently the mother received a prior dose.
3
Rule out the other presented interventions based on timing or contraindications.
Anti-D is unnecessary (Rh-positive); GBS screening is premature (done at 36-37 weeks); MMR is contraindicated (live vaccine); PCV20 is deferred in pregnancy.
Ensures the selected intervention is the singular correct choice for today's visit without conflicting with other guidelines.

Key Concept

Maternal Immunization Guidelines
Estimated Time:1m 15s
Rate this question

Topics

Preventive Care and Screening

More questions from this topic